Clinical Trials Browser

Phase 2 × Stomach Neoplasms × Oxaliplatin × Clear all

NCT06256328 2026-03-13

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT07070466 2026-03-06

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

Phase 2 Recruiting

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT06461910 2026-03-03

Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT05329766 2026-02-27

EDGE-Gastric

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT07432295 2026-02-25

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Neoplasm Metastasis, Stomach Neoplasms

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Phase 2 Active not recruiting

40 enrolled 67 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04379596 2026-02-23

DG-03

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05567835 2026-02-23

TOGAR

Phase 2 Terminated

Gastrointestinal

Stomach Neoplasms

NCT06109467 2026-02-09

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT04661150 2026-01-30

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

Phase 2 Active not recruiting

42 enrolled 9 charts

Gastrointestinal

Stomach Neoplasms

NCT07374250 2026-01-28

Huaxi

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT06576921 2025-12-23

Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06313801 2025-11-21

Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT01191697 2025-11-03

CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

Phase 2 Completed

37 enrolled 11 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT03505320 2025-10-20

ILUSTRO

Phase 2 Active not recruiting

Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT04363801 2025-10-09

DisTinGuish

Phase 2 Terminated

247 enrolled 38 charts

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT07194005 2025-09-26

Remission

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06253611 2025-09-22

BIG

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT03929666 2025-09-12

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT07165847 2025-09-10

Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT07007182 2025-09-05

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT07085273 2025-07-31

Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT03421288 2025-07-25

DANTE

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT05161572 2025-06-18

NeoRacing

Phase 2 Terminated

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT07018063 2025-06-12

YOUNG-NEOS

Phase 2 Not yet recruiting

Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT06914687 2025-04-06

Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT06881017 2025-03-18

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT04863430 2025-02-21

Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach

Phase 2 Withdrawn

Gastrointestinal

Stomach Neoplasms

NCT06730373 2024-12-31

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT03878472 2024-12-16

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT04745988 2024-11-15

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT04933227 2024-11-14

A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Phase 2 Terminated

Gastrointestinal

Stomach Neoplasms

NCT04937738 2024-11-06

PECORINO

Phase 2 Terminated

Gastrointestinal

Stomach Neoplasms

NCT03469557 2024-10-23

BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Stomach Neoplasms

NCT04515615 2024-09-19

Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT03382600 2024-06-11

KEYNOTE-659

Phase 2 Completed

100 enrolled 21 charts

Gastrointestinal

Stomach Neoplasms

NCT06451211 2024-06-11

Neo-ICEBOAT

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06447636 2024-06-07

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT02931890 2024-05-02

CRITICS-II

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT04908813 2024-04-15

Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT06341595 2024-04-02

Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06310473 2024-03-15

Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT04062656 2024-03-12

IMAGINE

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT03950271 2024-02-28

SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT05184803 2024-02-28

A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT04694183 2024-02-07

The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer

Phase 2 Completed

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT03283761 2024-02-06

FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma

Phase 2 Completed

39 enrolled 17 charts

Gastrointestinal

Stomach Neoplasms

NCT03472365 2024-01-11

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Phase 2 Completed

67 enrolled 12 charts

Gastrointestinal

Stomach Neoplasms

NCT06197438 2024-01-09

Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms